The relationship between the recurrence rate of genital warts and administration of quadrivalent human papilloma virus vaccine in women

In this cohort study a total of 203 women with genital warts, who were referred to gynecology clinic of Shahid Muftah in Yasuj city between 2019 and 2022, were examined and treated by a gynecologist and trained for injection of three doses of Gardasil vaccine after treatment. Of these, 138 women completed the study. Half of them who received three doses of the Gardasil vaccine, aligned in vaccinated group and the other half served as the unvaccinated group. In the vaccinated group, 8 individuals (11.6 %) experienced recurrence, compared to 15 individuals (21.7 %) in the unvaccinated group (p = 0.11). The overall number of recurrence among all participants was 23 (16.7 %). The average duration of treatment until recurrence was 43.6 ± 24.7 weeks in the vaccinated group and 16.4 ± 16.5 weeks in the unvaccinated group (P ≤ 0.017), underscoring the vaccine's preventive role in the recurrence of genital warts.